ELISpot is a method commonly used to detect cellular immune responses to viral vector-based gene therapies. We take a closer look at how the industry is working to harmonize best practices for developing & validating ELISpot assays for gene therapy development.
When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable of handling quick turnarounds and rescue projects. We look at an example of how BioAgilytix sprung to action to transform a troubled study.
We strive to foster an environment where our team members can continually grow within their role and within the company – not only upwards, but also into positions they come to find most suited to their unique skills and interests. In this Team Q&A session, we talk to Tatjana Ackermann, Quality Assurance Auditor, about her career path at BioAgilytix since starting in our European lab five years ago.
In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our team – including how she came to be our resident expert on IgE antibody testing on the ImmunoCAP platform.
The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less prevalent than IgG antibodies, a very sensitive detection method is required. We discuss why the ImmunoCAP platform provides an ideal system to analyze IgE-mediated drug hypersensitivities.
What are the advantages of using the Biacore™ T200 SPR System for immunogenicity assessments with a tiered approach? Our experts discuss.
Target interference can cause false positive ADA assay results and stall out promising drugs. This could have been the case for one study involving an MAb binding to a target protein which contained the dimerization interface – that is, until BioAgilytix stepped in.
The webinar I recently hosted with my colleague Lydia Michaut explored key challenges and trends in the immunogenicity assessment of gene therapy compounds. This recap highlights the critical questions that were answered.
By Dr. Arno Kromminga and Dr. Lydia Michaut
Gene therapy has experienced an exciting resurgence in the post-genomic era, but unwanted immunogenicity is still a concern. Our latest blog gives insight into the current concepts for designing an immunogenicity assessment strategy fitting the specific needs of a given gene therapy compound.
Flow cytometry is an ideal platform for many applications involving the study of complex cell populations. In the first blog of our new “The Fit for Flow” series, we discuss what makes flow cytometry the platform of choice for receptor occupancy (RO) studies.
Services
Platforms